| Company Name: |
Clearsynth Labs Limited
|
| Tel: |
+91-22-26355700 |
| Email: |
info@clearsynth.com |
| Products Intro: |
Product Name:(±)-Bupivacaine-d9
CAS:474668-57-0
Remarks:CS-C-01143
|
| Company Name: |
Nanjing Haolv Biotechnology Co.,Ltd
|
| Tel: |
025-84622273 02584622273; |
| Email: |
kexin.zhou@haolvbiotech.com |
| Products Intro: |
Product Name:(±)-Bupivacaine-d9 (butyl-d9)
CAS:474668-57-0
Purity:98% Package:5g;25g;100g
|
| Company Name: |
TOSUN PHARM
|
| Tel: |
020-61855200 13326451905 |
| Email: |
2881290884@qq.com |
| Products Intro: |
Product Name:Bupivacaine-d9
CAS:474668-57-0
Purity:98%以上 Package:10mg;50mg;100mg等多种规格 Remarks:REF-B04015
|
|
| | Bupivacaine-d9 Basic information |
| Product Name: | Bupivacaine-d9 | | Synonyms: | Bupivacaine-d9;rac-Bupivacaine-d9;Bupivacaine D9Q: What is
Bupivacaine D9 Q: What is the CAS Number of
Bupivacaine D9 Q: What is the storage condition of
Bupivacaine D9 Q: What are the applications of
Bupivacaine D9;2H9]-Bupivacaine | | CAS: | 474668-57-0 | | MF: | C18H28N2O | | MW: | 288.44 | | EINECS: | | | Product Categories: | | | Mol File: | 474668-57-0.mol |  |
| | Bupivacaine-d9 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml,DMSO: 25 mg/ml,Ethanol: 30 mg/ml | | form | A solid |
| | Bupivacaine-d9 Usage And Synthesis |
| Uses | (±)-Bupivacaine-d9 (butyl-d9) is an internal standard, useful for the detection of corticosteroids in human plasma. | | Biological Activity | Bupivacaine-d9 is intended for use as an internal standard for the quantification of bupivacaine by GC- or LC-MS. Bupivacaine is a sodium channel blocker and local anesthetic.1,2 It inhibits sodium currents in rat dorsal horn neurons in a concentration-dependent manner and inhibits synaptic transmission in rat sympathetic ganglia, increasing the firing threshold when used at a concentration of 200 nM.3,4 Bupivacaine (10 μM) blocks cardiac sodium channels in a use-dependent manner and inhibits respiration in cardiac cell mitochondria when palmitoyl-carnitine or acetyl-carnitine are used as substrates (IC50s = 0.78 and 0.37 mM, respectively).1,5 It also reduces thermal hyperplasia in a rat model of sciatic ligation injury when 0.6 ml of a 0.5% solution is administered into the perinerve space, and the duration of this effect is extended by co-administration of the NMDA receptor antagonist MK-801 .2 Formulations containing bupivacaine have been used as local anesthetics for surgery, oral surgery, and dental procedures and for anesthetic purposes in research studies using animals. | | References | 1.Arlock, P.Actions of three local anaesthetics: lidocaine, bupivacaine and ropivacaine on guinea pig papillary muscle sodium channels (Vmax)Pharmacol. Toxicol.63(2)96-104(1988)
2.Mao, J., Price, D.D., Mayer, D.J., et al.Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathyBrain Res.576(2)254-262(1992)
3.Olschewski, A., Hempelmann, G., Vogel, W., et al.Blockade of Na+ and K+ currents by local anesthetics in the dorsal horn neurons of the spinal cordAnesthesiology88(1)172-179(1998)
4.Tabatabai, M., and Booth, A.M.Mechanism of action of local anesthetics on synaptic transmission in the ratAnesth. Analg.71(2)149-157(1990)
5.Weinberg, G.L., Palmer, J.W., VadeBoncouer, T.R., et al.Bupivacaine inhibits acylcarnitine exchange in cardiac mitochondriaAnesthesiology92(2)523-528(2000) |
| | Bupivacaine-d9 Preparation Products And Raw materials |
|